Nath Bio-Genes (India) Ltd's Q4FY25 Quarter Results
- 1d ago
Result Summary
- Nath Bio-Genes (India) Ltd reported a 16.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 22.6% QoQ and - - YoY.
- The net profit decreased 1.1% QoQ and - - YoY.
- The earnings per share (EPS) of Nath Bio-Genes (India) Ltd stood at 1.9 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 43.45 | 37.35 | 0.00 | 16.3% | - |
Total Expenses | 41.16 | 33.56 | 0.00 | 22.6% | - |
Profit Before Tax | 3.23 | 3.79 | - | -14.8% | NaN% |
Tax | 0.62 | 1.14 | 0.00 | -45.6% | - |
Profit After Tax | 2.62 | 2.65 | 0.00 | -1.1% | - |
Earnings Per Share | 1.90 | 1.30 | 0.00 | 46.2% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nath Bio-Genes (India) Ltd is a company primarily engaged in the agriculture sector, focusing on the production and sale of hybrid and genetically modified seeds. The company's product line includes a variety of seeds such as cotton, paddy, maize, and vegetables, which are integral to agricultural productivity in India. Nath Bio-Genes has positioned itself as a leader in the seed industry, leveraging biotechnology to enhance crop yields and resistance to environmental stresses. Information about any recent major developments within the company or significant strategic initiatives is not available in the provided data.
Revenue
For the fourth quarter of the fiscal year 2025 (Q4FY25), Nath Bio-Genes (India) Ltd reported a total income of ₹43.45 crores, marking a robust quarter-over-quarter (QoQ) increase of 16.3% from ₹37.35 crores in the third quarter of fiscal year 2025 (Q3FY25). The year-over-year (YoY) comparison with the fourth quarter of fiscal year 2024 (Q4FY24) is not possible as the data for Q4FY24 is not provided. This substantial growth in revenue quarter-over-quarter suggests an upward trajectory in the company's sales performance during this period.
Profitability
In Q4FY25, the company's profit before tax (PBT) was ₹3.23 crores, which reflects a decrease of 14.8% QoQ from ₹3.79 crores in Q3FY25. The tax expense for Q4FY25 was ₹0.62 crores, a significant reduction of 45.6% compared to ₹1.14 crores in Q3FY25. Consequently, the profit after tax (PAT) for Q4FY25 stood at ₹2.62 crores, showing a slight decline of 1.1% QoQ from ₹2.65 crores in Q3FY25. The earnings per share (EPS) increased by 46.2% QoQ, from ₹1.30 in Q3FY25 to ₹1.90 in Q4FY25. These figures highlight the company's financial performance in terms of profitability, with a notable reduction in tax expenses contributing to a relatively stable net profit margin despite a decline in pre-tax profit.
Operating Metrics
The total expenses for Nath Bio-Genes in Q4FY25 were reported at ₹41.16 crores, representing a 22.6% increase QoQ from ₹33.56 crores in Q3FY25. This rise in expenses outpaced the revenue growth for the same period, which may have impacted the company's profitability margins. The lack of YoY expense data precludes further analysis of longer-term trends. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio cannot be calculated due to insufficient data on the company's share price, debt levels, and asset composition. The financial data provided focuses on income, expenses, and profitability metrics, offering insights into the company's operational efficiency over the recent quarter.
